3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA
Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Annual Report to Security Holders
Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Director Resignation - Mary Fisher Steps Down from Dermata Board
Dermata Therapeutics Dismisses Baker Tilly as Independent Accountant
Dermata Therapeutics Increases Common Stock Offering by $705,000
Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Termination of License Agreement with Villani, Inc. by Dermata Therapeutics
Q1
Q3
Q2
FY 2024
Amended Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload